Indaptus Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Indaptus Therapeutics, Inc. (INDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.70% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-13
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.70%.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.00%, a 14.29% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.50%, a 105.88% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.70%.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 0.00% change from fiscal 2024.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 8.11% increase from fiscal 2023.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.70%, a 68.18% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.20%, a 214.29% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 3.70% 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 3.70% 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | 4.00% 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 4.10% 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | 4.10% 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | 4.10% 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | 4.00% 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | 3.70% 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 3.70% 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | 3.60% 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | 3.50% 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | 2.20% 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | 2.20% 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | 1.80% 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | 1.70% 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | 0.70% 10-K · filed 2023-03-17 | ||||
| 2021-08-04 | 0.71% 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | 1.42% 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |